[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100605467":3},{"organization":4,"outcomesModule":7,"designInfo":17,"detailedDescription":11,"studyPopulation":11,"armGroups":23,"interventions":34,"overallOfficials":11,"centralContacts":43,"locations":49,"responsibleParty":68,"collaborators":11,"id":71,"slug":11,"hasResults":72,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":11,"eligibilityCriteria":76,"healthyVolunteers":72,"sex":77,"minAge":78,"maxAge":79,"enrollmentInfo":80,"targetDuration":11,"studyType":83,"phases":84,"briefSummary":86,"conditions":87,"keywords":11,"overallStatus":90,"whyStopped":11,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"Shalamar Institute of Health Sciences","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":11,"otherOutcomes":11},[9,13],{"measure":10,"description":11,"timeFrame":12},"Proportion of Participants with ISGA sucess ( clear \u002F almost clear from baseline) at day 28.",null,"28 days",{"measure":14,"description":15,"timeFrame":16},"Change in ISGA from baseline to day 28.","ISGA uses a 5-point scale (0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe); negative change indicates improvement.","Baseline, Day 14, Day 28",{"allocation":18,"interventionModel":19,"interventionModelDescription":11,"primaryPurpose":20,"observationalModel":11,"timePerspective":11,"maskingInfo":21},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":22,"maskingDescription":11,"whoMasked":11},"NONE",[24,30],{"label":25,"type":26,"description":27,"interventionNames":28},"Crisaborole 2% Ointment","ACTIVE_COMPARATOR","Twice daily application to affected areas for 28 days",[29],"Drug: Crisaborole 2%",{"label":31,"type":26,"description":27,"interventionNames":32},"Tacrolimus 0.1% Ointment",[33],"Drug: Tacrolimus 0.1%",[35,40],{"type":36,"name":37,"description":38,"armGroupLabels":39,"otherNames":11},"DRUG","Crisaborole 2%","Apply thin layer to affected skin daily for 28 days.",[25],{"type":36,"name":41,"description":38,"armGroupLabels":42,"otherNames":11},"Tacrolimus 0.1%",[31],[44],{"name":45,"role":46,"phone":47,"phoneExt":11,"email":48},"Kheziema Maryum","CONTACT","0310-4999940","doc.kheziemamaryum@gmail.com",[50],{"facility":51,"status":11,"city":52,"state":53,"zip":54,"country":55,"countryCode":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":63},"Shalamar Hospital Lahore","Lahore","Punjab Province","54000","Pakistan","PK",{"type":58,"coordinates":59},"Point",[60,61],74.35071,31.558,{"lat":61,"lon":60},[64],{"name":65,"role":46,"phone":66,"phoneExt":11,"email":67},"Shalamar Hospital Lahore Shalamar Hospital Lahore","(042)111205205","info@sihs.org.pk",{"type":69,"investigatorFullName":45,"investigatorTitle":70,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Principal Investigator","100605467",false,"NCT07162896","Crisaborole 2% Versus Tacrolimus 0.1% in Children With Mild to Moderate Atopic Dermatitis","Efficacy and Safety of Crisaborole 2% Versus Tacrolimus 0.1% in Children With Mild to Moderate Atopic Dermatitis","Inclusion Criteria:\n\n* Age 2-18 years Both genders Clinically diagnosed mild to moderate atopic dermatitis Body surface area (BSA) \\\u003C30%\n\nExclusion Criteria:\n\nActive viral, bacterial, or fungal skin infection at the treatment site\n\nRecent use of topical corticosteroids, calcineurin inhibitors, PDE4 inhibitors, or immunosuppressive medication within past 2 weeks\n\nKnown hypersensitivity to study medications or components\n\nChronic inflammatory conditions (e.g., psoriasis and seborrheic dermatitis) that may interfere with evaluation","ALL","2 Years","18 Years",{"count":81,"type":82},66,"ESTIMATED","INTERVENTIONAL",[85],"PHASE3","This randomized, open-label, parallel-group study will compare the efficacy and safety of Crisaborole 2% ointment and Tacrolimus 0.1% ointment in children with mild to moderate atopic dermatitis. A total of 66 participants will be randomized (1:1) to receive either Crisaborole or Tacrolimus, applied twice daily to affected areas for 28 days. Primary endpoint is proportion of participants achieving Investigator's Static Global Assessment (ISGA) success (clear\u002Falmost clear with ≥2-point improvement from baseline) at Day 28. Safety assessments include adverse events and local application site reactions.",[88,89],"Atopic Dermatitis","Atopic Dermatitis (AD)","NOT_YET_RECRUITING","2025-08-31",{"date":93,"type":94},"2025-09-09","ACTUAL",{"date":96,"type":82},"2026-06",{"date":98,"type":82},"2027-06",{"name":5,"class":6},1]